Sort
30,917 grants matching “tumor microenvironment”
Theranostic for gastric cancer
$1,065,500Valerie Humblet · Collagen Medical, Llc · R44 · FY2025 · CA
RNAi Screening in Hematopoietic Cells
$1,065,285Iain Fraser · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
$1,064,245Douglas F Nixon · Feinstein Institute For Medical Research · R01 · FY2025 · CA
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer
$1,063,904Akash Patnaik · University Of Chicago · R01 · FY2025 · CA
A Multimodal 3D Atlas of Colorectal Cancer Across Ages of Onset
$1,063,411Ken S Lau · Vanderbilt University · U01 · FY2024 · CA
Understanding Hemotopoietic Neoplasias using Humanized Mice
$1,063,218Richard A Flavell · Yale University · R01 · FY2010 · CA
Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation
$1,062,441Robert J Coffey · Vanderbilt University Medical Center · R35 · FY2024 · CA
Towards targeting the lymphoma microenvironment
$1,062,000Hans-Guido Wendel · Sloan-Kettering Inst Can Research · R35 · FY2021 · CA
Exploring the Role of Nitrogen Metabolism in Cancer
$1,062,000Craig B Thompson · Sloan-Kettering Inst Can Research · R35 · FY2025 · CA
Towards targeting the lymphoma microenvironment
$1,062,000Hans-Guido Wendel · Sloan-Kettering Inst Can Research · R35 · FY2025 · CA
Targeting intratumor heterogeneity in breast cancer
$1,060,812Kornelia Polyak · Dana-Farber Cancer Inst · R35 · FY2025 · CA
Targeting intratumor heterogeneity in breast cancer
$1,060,812Kornelia Polyak · Dana-Farber Cancer Inst · R35 · FY2022 · CA
The Role of the Integrated Stress Response in Cancer
$1,060,147Constantinos Koumenis · University Of Pennsylvania · P01 · FY2022 · CA
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
$1,059,896Song Yao · Roswell Park Cancer Institute Corp · UG3 · FY2021 · CA
TGF-betas in breast cancer progression
$1,059,250Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,058,087Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Collaborative Protein Technology Resource - Nano-Scale Protein Analysis Section
$1,057,804Jinqiu Chen · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
Interacting Signaling Pathways that Initiate Squamous Cell Carcinogenesis
$1,057,469Stuart H. Yuspa · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Pathways that Suppress or Accelerate Premalignant Progression of Squamous Cancer
$1,057,469Stuart H. Yuspa · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Bladder Cancer Program
$1,057,180Andrea Apolo · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Preclinical drug development in pancreas cancer
$1,056,492Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
A FUNCTIONAL GENOMICS APPROACH TO IDENTIFY RENAL CELL CARCINOMA ANTIGENS TARGETED BY T CELLS IN THE TUMOR MICROENVIRONMENT.
$1,056,000Fred Hutchinson Cancer Center · · FY2021 · Defense Health Agency
Integrating systems immunology with immunometabolism and cancer immunity
$1,055,460Hongbo Chi · St. Jude Children'S Research Hospital · R35 · FY2022 · CA
Integrating systems immunology with immunometabolism and cancer immunity
$1,055,460Hongbo Chi · St. Jude Children'S Research Hospital · R35 · FY2023 · CA
Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotides
$1,054,354Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA